No abstract available
MeSH terms
-
Consensus
-
Cost-Benefit Analysis
-
Diabetes Mellitus, Type 2* / diagnosis
-
Diabetes Mellitus, Type 2* / drug therapy
-
Glucagon-Like Peptide-1 Receptor / agonists
-
Glucose
-
Humans
-
Hypoglycemic Agents / therapeutic use
-
Sodium
-
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
-
Symporters*
Substances
-
Sodium-Glucose Transporter 2 Inhibitors
-
Glucagon-Like Peptide-1 Receptor
-
Hypoglycemic Agents
-
Sodium
-
Symporters
-
Glucose